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1. Abstract 1 
 2 
Mutations in ATP13A2 lead to Kufor-Rakeb syndrome, a parkinsonism with dementia. 3 
ATP13A2 belongs to the P-type transport ATPases, a large family of primary active 4 
transporters that exert vital cellular functions. However, the cellular function and transported 5 
substrate of ATP13A2 remain unknown. To discuss the role of ATP13A2 in 6 
neurodegeneration, we first provide a short description of the architecture and transport 7 
mechanism of P-type transport ATPases. Then, we briefly highlight key P-type ATPases 8 
involved in neuronal disorders such as the copper transporters ATP7A (Menkes disease), 9 
ATP7B (Wilson disease), the Na
+
/K
+
-ATPases ATP1A2 (familial hemiplegic migraine) and 10 
ATP1A3 (rapid-onset dystonia parkinsonism). Finally, we review the recent literature of 11 
ATP13A2 and discuss ATP13A2’s putative cellular function in the light of what is known 12 
concerning the functions of other, better-studied P-type ATPases. We critically review the 13 
available data concerning the role of ATP13A2 in heavy metal transport and propose a 14 
possible alternative hypothesis that ATP13A2 might be a flippase. As a flippase, ATP13A2 15 
may transport an organic molecule, such as a lipid or a peptide, from one membrane leaflet to 16 
the other. A flippase might control local lipid dynamics during vesicle formation and 17 
membrane fusion events. 18 
 19 
2. Introduction 20 
 21 
Neurodegenerative diseases, the fourth leading cause of death in developed countries, are 22 
characterized by progressive loss of neurons within the central nervous system leading to 23 
motor and cognitive dysfunction. Alzheimer’s disease (AD) and Parkinson’s disease (PD) are 24 
the most common neurodegenerative disorders (1, 2). Their prevalence is increasing as a 25 
consequence of the ageing population and lack of successful treatments. PD is a progressive 26 
movement disorder characterized by severe loss of dopaminergic neurons in the substantia 27 
nigra pars compacta (2). As a consequence of cell death, dopamine content is reduced in the 28 
basal ganglia, leading to the motor symptoms observed in patients. The cardinal symptoms of 29 
PD are resting tremor, muscle rigidity (stiffness of limbs), bradykinesia (slowness of 30 
movements) and postural instability (gait or balance problems) (reviewed in (1-3)).  31 
 32 
A second hallmark of PD is the accumulation of aggregated α-synuclein into Lewy bodies 33 
(LBs) (4). Moreover, mutations in the SNCA (α-synuclein) gene were found to be associated 34 
with the familial cases of early-onset Parkinson's disease (5). α-synuclein is able to form 35 
amyloid fibrils, β-sheet structures prone to aggregation, which is its main pathogenic feature. 36 
α-synuclein overexpression results in endoplasmic reticulum (ER) stress, vesicle trafficking 37 
defects, impairment of the ubiquitin-proteasome system and mitochondrial dysfunction 38 
(reviewed in (6, 7)). 39 
  40 
α-synuclein is mainly found at the presynaptic terminals of neurons (8). In presynaptic 41 
terminals, α-synuclein interacts with the membranes of synaptic vesicles and associated 42 
proteins, where it appears to be a critical regulator of vesicle dynamics at the synapse 43 
(reviewed in (6, 7)). It acts as a trafficking partner of synaptobrevin II (sybII) (9). At this 44 
location, α-synuclein facilitates the entry of sybII into SNARE complexes, which is key step 45 
in the exocytotic fusion of synaptic vesicles with the presynaptic terminal (9, 10). The acidic 46 
C-terminal of α-synuclein interacts with sybII whereas its N-terminal membrane-associated 47 
region is an inducible amphipathic α-helix that obtains its structure only after contact with the 48 
membrane (6, 7). The amphipathic helix does not enter the membrane bilayer, but aligns itself 49 
parallel to the bilayer axis. Amphipathic α-helices are found in several proteins that regulate 50 
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membrane vesicle trafficking and it is becoming increasingly clear that they function as 1 
membrane curvature sensors (11-13). Synucleins have been shown to both induce and sense 2 
membrane curvature (14-16), which can have a significant impact on the basal fusogenic 3 
properties of synaptic vesicles. 4 
 5 
α-synuclein aggregates accumulate in PD and are cleared via various routes, mainly including 6 
the ubiquitin-proteasome system, autophagy and lysosomal degradation pathways (17, 18). 7 
Besides the accumulation of misfolded proteins, PD is further associated with mitochondrial 8 
dysfunction generating reactive oxygen species (ROS) and oxidative stress (6, 19). These 9 
phenomena mutually affect each other as diseased mitochondria generate more ROS, which in 10 
turn exacerbates protein folding defects. Thus clearance of dysfunctional or damaged 11 
mitochondria and proper functioning of the protein quality control are essential for neuronal 12 
fitness and survival, but are impaired in PD (20-23). Protein quality control depends on both 13 
the proteasome and lysosome. The lysosome mediates end-stage degradation of obsolete or 14 
damaged cytoplasmic material, including protein aggregates and organelles such as 15 
mitochondria, through autophagy pathways (17, 18, 21-24).  16 
 17 
ATP13A2 is a late endosomal/lysosomal P5-type transport ATPase that is emerging as a 18 
critical regulator of lysosomal functions (25-28). Mutations in the ATP13A2 gene, belonging 19 
to the PARK9 PD susceptibility locus, lead to the Kufor-Rakeb syndrome (KRS), a severe 20 
early-onset autosomal recessive form of PD with dementia (25). Overexpression of ATP13A2 21 
suppresses α-synuclein toxicity. This links two genetic risk factors of PD, i.e. ATP13A2 and 22 
α-synuclein, highlighting the central role of ATP13A2 in PD (29). Loss of ATP13A2 function 23 
is also associated with neuronal ceroid lipofuscinosis, a lysosomal storage disorder (30-32). 24 
 25 
This review will focus on ATP13A2 as an orphan member of the family of P-type transport 26 
ATPases. P-type ATPases are a large family of evolutionarily related primary transporters 27 
present in Archaea, Bacteria and Eukarya (reviewed in (33, 34)). They use the energy derived 28 
from ATP hydrolysis to transport various substrates, ranging from ions to lipids, across 29 
biological membranes against their concentration gradients. P-type ATPases are crucial for 30 
the generation of electrochemical gradients, which fuel vital cellular processes, such as 31 
secondary transport, excitability, vesicular transport and osmotic balance.  32 
 33 
In the following sections we will give a short description of the architecture and transport 34 
mechanism of classical P-type transport ATPases. Then, we will provide an overview of those 35 
P-type ATPases that are implicated in neuronal disorders. Finally, we will review the recent 36 
literature of ATP13A2 and use available knowledge on P-type ATPase functions to discuss 37 
ATP13A2’s putative cellular function and pathological role in PD.  38 
 39 
3. The family of P-type ATPases 40 
 41 
3.1. General features of P-type ATPases 42 
 43 
P-type ATPases are biological pumps omnipresent in all forms of life, which are recognized 44 
by several conserved signature motifs associated with their catalytic mechanism (35). The 45 
main characteristic of all P-type ATPases is the formation of an acid-stable aspartyl phosphate 46 
intermediate during the catalytic cycle (hence the name P-type). The phosphorylated Asp 47 
residue is located in a highly conserved DKTG sequence motif located in the cytoplasmic part 48 
of the proteins. The events of auto-phosphorylation and auto-dephosphorylation are tightly 49 
coupled to substrate binding, transport and release.  50 
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 1 
According to sequence comparison and phylogenetic analysis, the P-type transport ATPase 2 
family can be classified into five distinct subfamilies (P1–P5), which can be further divided 3 
into additional subgroups (A, B, etc.) (35) (reviewed in (33, 34)). Importantly, the 4 
phylogenetic division correlates well with differences in the preferred transport substrates. 5 
The P1-P3 ATPases are well-characterized ion pumps: the P1A are part of bacterial K
+
 6 
transport systems, the P1B transport heavy metals, the P2A and P2B are Ca
2+
 pumps, the P2C 7 
Na
+
/K
+
- and H
+
/K
+
-pumps are found in animals, the P2D are Na
+
 pumps in fungi and mosses 8 
and the plasma membrane H
+
 pumps of P3A are present in fungi and plants. The P3B 9 
corresponds to a small group of bacterial Mg
2+
 transporters. In contrast to inorganic ion 10 
transport, P4 ATPases participate in lipid flipping across membranes, generating membrane 11 
curvature and exposing or removing relevant signalling lipids. The substrate specificity of the 12 
last subfamily, the P5 ATPases, has yet to be revealed.  13 
 14 
Based on the conserved P-type ATPase motifs, 36 human genes are recognized and annotated 15 
in databases to encode for P-type ATPases. These include 2 copper-ATPases, 4 Na
+
/K
+
-16 
ATPases, 2 H
+
/K
+
-ATPases, 9 Ca
2+
-ATPases, 14 putative lipid flippases and 5 P5-type 17 
ATPases with unknown substrate specificity (ATP13A1-5). Fig. 1 displays the phylogenetic 18 
relationship of these 36 human P-type ATPases and their orthologues in key animal model 19 
organisms. Many P-type ATPases display broad expression profiles and fulfill many 20 
housekeeping functions, while the expression of other P-type ATPases is restricted to specific 21 
tissues e.g. brain, heart, skeletal muscle, etc.  22 
 23 
P-type ATPases use metabolic energy (ATP) to actively pump substrates against an 24 
electrochemical gradient. To prevent backflow of transported ligand(s), P-type ATPases use 25 
an alternating access mechanism (Fig. 2). After substrate binding from one side, the access 26 
pathways from both sides of the membrane are transiently closed, effectively occluding the 27 
transported ion(s) in the membrane domain, before releasing them to the other side of the 28 
membrane. In addition, the affinity towards the substrate is different at both sides of the 29 
membrane. High affinity binding occurs at the side of the membrane with low substrate 30 
availability, whereas a drop in the affinity at the other side of the membrane leads to 31 
spontaneous release. These two features allow P-type ATPases to generate steep 32 
concentration and charge gradients (33, 34).  33 
 34 
The transport mechanism of P-type ATPases can be described by the model of Post-Albers 35 
((36), reviewed in (33, 34)). During each catalytic cycle, the pumps oscillate between four 36 
major conformations (Fig. 2): E1, E1P, E2P and E2. The E1 state displays high-affinity ion-37 
binding sites that are exposed to the cytosol. Upon ion binding, the protein reacts with an ATP 38 
nucleotide catalyzing auto-phosphorylation generating the E1P state in which ions are 39 
occluded. Then, the protein undergoes an often rate limiting transition to the E2P state where 40 
the transport binding sites are transformed into low-affinity sites facing the extra-cytosolic 41 
side of the membrane. This releases the ion(s) and allows the binding of specific 42 
counterion(s). This binding triggers E2P auto-dephosphorylation, returning to the E2 ground 43 
state in which counter-ions are occluded. All P-type ATPases are inhibited by orthovanadate, 44 
an inorganic phosphate mimic that locks the enzyme in the E2P conformation. Finally, the 45 
transition to E1 allows release of counter-ions at the cytosolic side to re-initiate the catalytical 46 
cycle.  47 
 48 
The transport process can be overall electrogenic if translocation occurs of an unequal amount 49 
of charges at both sides of the membrane. Examples are the Na
+
/K
+
-ATPase, which transports 50 
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two Na
+
 ions out of the cell in exchange for three K
+
 ions per hydrolysed ATP, and the 1 
SERCA Ca
2+
-ATPases, which transport two Ca
2+
 ions from the cytoplasm to the lumen of the 2 
ER/SR for two to three H
+
 in the other direction. Other P-type ATPases transport only in one 3 
direction using either the forward E1 to E1P step to bind the transported substrate (P1B 4 
copper-ATPase, P3 H
+
-ATPase) while others use the E2P step for substrate binding (P4 lipid 5 
flippases) (33, 34).  6 
 7 
3.2. The P-type ATPase architecture 8 
 9 
The two archetypical members of the P-type ATPase family are the sarco(endo)plasmic 10 
reticulum (SR/ER) Ca
2+
-ATPase SERCA1a and the (α1 subunit of) Na+/K+-ATPase for which 11 
there is a wealth of structural and kinetic information. SERCA1a was the first P-type ATPase 12 
to have its structure solved at high resolution (37), providing detailed insights into the overall 13 
domain organization of a P-type ATPase. Since then, several other conformational states of 14 
SERCA1a have been resolved using several inhibitors, transition analogues and nucleotides 15 
locking the protein in intermediate steps of the transport mechanism. Together with a strong 16 
biochemical characterization and extensive mutagenesis, this has culminated in a detailed 17 
description of the transport mechanism of the Ca
2+
-ATPase at atomic resolution, which 18 
provides the scaffold to understand the transport process in other P-type ATPases. For a 19 
careful discussion of this topic, the reader is referred to excellent in depth reviews and 20 
references in (34, 38, 39).  21 
 22 
Crystal structures have also been presented for other P-type ATPases including the H
+
-23 
ATPase of plants (40), the Na
+
/K
+
-ATPase (41-44) and the copper-ATPase of Legionella 24 
pneumophila (45) (Fig. 3). Comparison of these structures has revealed that P-type ATPases 25 
share a strikingly similar fold despite strong sequence divergence. Four principal domains are 26 
recognized, which are conserved throughout the family: three cytoplasmic domains 27 
(nucleotide-binding, N; phosphorylation, P; actuator, A) and a transmembrane (TM) domain 28 
(M domain) (Fig. 3). During the catalytic transport process the N-domain binds ATP and 29 
serves as a built-in protein kinase, which auto-phosphorylates the P-domain. The A-domain 30 
acts as an intrinsic protein phosphatase dephosphorylating the P-domain later in the catalytic 31 
cycle. The process of phosphorylation and dephosphorylation is tightly coupled to formation 32 
and deformation of high-affinity transport-binding sites in the M domain by an allosteric 33 
mechanism (34, 38, 39).  34 
 35 
The N-domain is the least conserved cytoplasmic domain among P-type ATPases and forms 36 
the ATP binding pocket. It is situated as a large insert into the P-domain sequence stretch and 37 
is connected by a highly flexible hinge region linking the N- and P-domains (37). The 38 
strongly conserved P-domain contains the P-type ATPase fingerprint with the critical Asp 39 
residue (DKTG). During each catalytic cycle, the Asp residue is alternately phosphorylated 40 
and dephosphorylated by the N-domain and the A-domain, respectively. A Lys in the 41 
nucleotide interaction site of the N-domain (KGAPE) interacts with the adenine ring of ATP 42 
delivering the γ-phosphate to the active-site residue of the P-domain. This reaction renders a 43 
high-energy aspartyl phosphate intermediate. Subsequently, the A-domain subjects the bond 44 
to hydrolysis, catalyzed by the Glu residue in the highly conserved signature motif TGE (34, 45 
38, 39).  46 
 47 
The M-domain, the largest of the four principal domains, comprises six to twelve α-helices 48 
(46) and plays a crucial role in substrate binding and transport. The cytoplasmic domains are 49 
connected to the M-domain by five flexible linker regions, four in P1-type ATPases (34). The 50 
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substrate translocation pathways are centred on the M1–M6 segments. M4 is critically 1 
important for substrate specificity and coordinating the substrate in the binding pocket. The 2 
sequence of the M4 region thus diverges between the five P-type subfamilies, corresponding 3 
to the difference in substrate specificities. M4 involves a highly conserved Pro residue, which 4 
induces unwinding of M4. This twist exposes backbone carbonyl oxygens that are used to 5 
coordinate the transported ligand (34).  6 
 7 
P-type ATPases also hold extended N- or C-terminal tails that regulate pump activity by intra-8 
molecular interaction (47) or via interaction of regulatory proteins (48). The extensions may 9 
in addition control subcellular localization (49) or substrate delivery (45). Often, the N and C 10 
termini are auto-inhibitory, preventing the activation of the transporter and requiring 11 
additional stimuli for pump activation (50, 51).  12 
  13 
3.3. The P-type ATPase ion transport cycle 14 
 15 
To translocate substrates across the membrane, P-type pumps undergo extensive 16 
conformational changes, which are driven by ATP hydrolysis. In the next section, the general 17 
catalytic mechanism of P-type ATPases will be explained based on the Ca
2+
 transport cycle of 18 
the SERCA1a pump (based on references in (34, 38, 39)). 19 
 20 
Ca
2+
 entry and binding: E2  E1 · 2Ca2+  21 
At the start of the catalytic cycle, cytosolic Ca
2+
 ions interact with the high-affinity binding 22 
sites in the M-domain in the E1 conformation. The binding of the two Ca
2+
 ions is sequential 23 
and cooperative. The first Ca
2+
 proceeds to site I where its binding repositions a critical Asp 24 
residue on M6 (D800), which now forms the second Ca
2+
 binding site II. Upon binding of the 25 
second Ca
2+
, the gating residue E309 on M4 will capture the second Ca
2+
 ion in site II.  26 
 27 
Phosphorylation and occlusion: E1 · 2Ca
2+
  E1∼P·2Ca2+ 28 
Via the induced fit mechanism of Ca
2+
 binding, the rearrangement of the TM helices is 29 
transmitted to the P-domain creating a Mg
2+
-binding site near the critical Asp residue (Asp
351
 30 
in SERCA1a). Presence of Mg
2+
 is essential as this cofactor decreases the electrostatic 31 
repulsion of the γ-phosphate of ATP by the negatively charged Asp and hence, allows 32 
phosphate transfer. In this way, ATPase activity of P-type transporters in the cytosolic 33 
domains is tightly coupled to the ion binding in the M-domain, preventing unnecessary ATP 34 
hydrolysis. The transition towards the intermediate E1∼P phosphorylated state bends the P-35 
domain and tilts the A-domain that rests on the P-domain. This exerts strain on the linkers 36 
between the A-domain and M1, M2 and M3 of the M-domain. As a result, M1-M2 is partially 37 
lifted out of the membrane forcing E309 in a fixed position, which closes the Ca
2+
 entry path 38 
(occlusion). 39 
 40 
Ca
2+
 release: E1∼P  E2-P  41 
Following complete γ-phosphate transfer, the ATP-mediated connection between the N- and 42 
P-domains is lost. As a consequence, the pump relaxes and the N-domain moves away from 43 
the catalytic site and stretches the linker region between the M3 helix and the A-domain. The 44 
generated tension triggers rotation of the A-domain and results in transition to the low-energy 45 
E2P state. The significant conformational changes associated with the E1P to E2P transition is 46 
the rate-limiting step in the catalytical cycle. The rearrangement of the pump opens the 47 
luminal exit pathway for Ca
2+
 by spreading out M1/M2 and M3/M4 away from M5/M6. In 48 
addition, this reduces the affinity of the Ca
2+
-binding sites promoting the luminal release of 49 
Ca
2+
. In exchange, two to three H
+
 ions bind with high affinity to the E2P state leading to 50 
7 
 
occlusion of the luminal gate and further rotation of the A-domain. The A-domain rotation 1 
also brings the TGE loop closer to the phosphorylation site, shielding the aspartyl-phosphate 2 
by restricting the access of ADP or water.  3 
 4 
Dephosphorylation and occlusion: E2-P  E2  5 
The Ca
2+
-ATPase pump is reset to E1 by a series of reversal reactions leading to E2P 6 
dephosphorylation and proton countertransport. Entry of a water molecule induces a new 7 
rotation of the A-domain, which now precisely positions the Glu of the TGE-loop and the 8 
water molecule to catalyze an attack on the aspartyl phosphate. The rotation of the A-domain 9 
also repositions M1/M2 and the cation-binding site with the protons becomes occluded. 10 
Thereafter, the A-domain disengages from the phosphorylation site resulting in transition of 11 
the E2 state to the relaxed E1 conformation associated with release of the counterions. 12 
 13 
3.4. Domain organization and signature motifs in P5B-type ATPases 14 
 15 
In comparison with the well-studied SERCA1a Ca
2+
 pump, little is known about the P5-type 16 
ATPases to which ATP13A2 belongs. P5-type ATPases are found in all eukaryotic genomes, 17 
but are absent in bacterial genomes (52, 53). Based on the conservation of residues in the 18 
putative transport binding sites (53) and on their predicted TM topology (52), the P5 19 
subfamily can be divided into two groups, P5A and P5B (Fig. 1 and 3). Exactly one P5A 20 
(ATP13A1 in humans) and at least one P5B isoform is found in all eukaryotic genomes, 21 
except for land plants, which have lost the P5B genes (53). Multiple P5B isoforms exist in 22 
higher vertebrates (four in humans, ATP13A2-5) and some invertebrate lineages (three in 23 
Caenorhabditis elegans, CATP-5 to 7).  24 
 25 
The P5-ATPase membrane topology is unusual (52). In addition to the 10 classical TM 26 
helices, two extra TM spanning helices are predicted in the N terminus of the P5A ATPases 27 
(Ma and Mb), whereas the P5B group is marked by a single predicted N-terminal TM helix 28 
(Ma). Therefore, the P5A would consist of 12 and the P5B of 11 TM helices. The poor 29 
sequence conservation of the extra N-terminal helices suggest that they are not critical for 30 
substrate coordination during transport (52). Instead, as in other P-type ATPases, the N-31 
terminal region may directly function as a regulator of catalytic function or serve as the 32 
docking site for other regulatory proteins (45). Of all P-type ATPases, only the P5 and the 33 
P1B heavy metal pumps contain additional N-terminal membrane-spanning segments (Fig. 3). 34 
The structure of a P1B pump, the CopA copper transporter, was recently solved (45). The 35 
structure clearly depicts that the Mb forms an N-terminal docking platform for the binding of 36 
a copper chaperone, which delivers copper to the pump directly, or via the N-terminal heavy 37 
metal binding domains (45). Interestingly, also the P5 ATPases contain conserved Pro or Gly 38 
residues at a similar position in the additional N-terminal membrane helices (Mb for P5A 39 
ATPases (52) and Ma for P5B ATPases). In analogy herewith, the extended N terminus of the 40 
P5 may follow a similar fold as in the P1B, representing a docking platform for substrate 41 
delivery.  42 
 43 
Like other P-type ATPases, P5 isoforms, including ATP13A2, contain the key signature 44 
motifs KGAPE for ATP coordination (N-domain), DKTG for auto-phosphorylation (P-45 
domain) and TGE for dephosphorylation (A-domain) (25, 54). This indicates that P5-ATPases 46 
like other P-type ATPases catalyze the hydrolysis of ATP to auto-phosphorylate the enzyme 47 
on a conserved Asp residue in the P-domain.  48 
 49 
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The presence of a highly conserved M4 region within P5 ATPases indicates that in P5-type 1 
ATPases the hydrolysis of ATP may be coupled to the transport of a ligand close to the M4 2 
region (52, 53). Spontaneous auto-phosphorylation has already been observed for the yeast 3 
P5A ATPase Spf1p and the plant P5A ATPase HvP5A1 (55, 56), but so far it remains unclear 4 
whether P5B-ATPases such as ATP13A2 also form a phospho-intermediate. 5 
 6 
The M4 segment of the P5-type ATPase corresponds to the putative substrate binding site and 7 
contains a double Pro in (PPxxP) (52, 53). This may exacerbate the twist of the M4 segment 8 
imposed by the initial Pro, which might have a significant impact on the mechanism of 9 
substrate coordination and transport. P5A sequences contain a PP(E/D)xPx(E/D) motif, 10 
whereas P5B sequences are characterized by a PP(A/V)xP(A/V)x motif (52, 53) (Fig. 4). The 11 
negative charges in the unwound M4 helix of P5A compared to the corresponding 12 
hydrophobic residues in P5B may suggest that both subgroups display different substrate 13 
specificities (52, 53). For this reason, we will focus only on the P5B ATPases in this review. 14 
 15 
4. P-type ATPases and neurodegeneration 16 
 17 
P-type ATPases play important roles in the nervous system, ranging from regulation of Ca
2+
 18 
homeostasis, osmotic balance, electrical excitability, uptake of trace elements to vesicular 19 
transport processes. It is therefore not surprising to see that loss-of-function mutations in 20 
many P-type ATPase isoforms are detrimental for neuronal functions. In the following 21 
sections we will provide a short overview of those P-type ATPases that according to genetic 22 
information are implicated in neurological disorders (Table 1).  23 
 24 
4.1. P1B-type ATPases in neurological disorders 25 
 26 
The P1B-type ATPase subfamily consists of the two copper-transporting isoforms in human, 27 
ATP7A and ATP7B. ATP7A is ubiquitously expressed in all tissues, including the brain, but 28 
except the liver, regulating homeostatic maintenance of cell copper levels. ATP7B is highly 29 
expressed in the liver. Mutations in ATP7A are associated with Menkes disease (MD) (57-30 
59), while ATP7B mutations cause Wilson's disease (WD) (60) (reviewed in (61-63)). 31 
 32 
4.1.1. ATP7A 33 
 34 
Mutations in ATP7A are associated with MD, an X-linked recessive disorder characterized by 35 
progressive neurodegeneration and connective tissue dysfunction (57-59). The clinical 36 
manifestations of MD include severe seizures associated with cerebral atrophy, vascular 37 
abnormalities, kinky hair structure, hypopigmentation, growth retardation and death in early 38 
childhood. These features originate from a generalized copper deficiency that triggers 39 
dysfunction of several cuproenzymes (63). ATP7A mutations also underlie occipital horn 40 
syndrome (OHS), a milder disease with moderate neurologic symptoms and prominent 41 
connective tissue disturbances (63). Recently, a novel ATP7A-related disease phenotype was 42 
discovered, spinal muscular atrophy, distal, X-linked 3 (SMAX3), which is characterized by 43 
atrophy of the lower limb muscles (64). 44 
 45 
ATP7A is targeted to the trans-Golgi network from where it supplies copper to the copper-46 
dependent enzymes as they migrate through the secretory pathway. Under conditions of 47 
elevated copper, ATP7A relocalizes to the plasma membrane where it promotes the efflux of 48 
copper from cells (49). To date, over 500 disease-causing variations of ATP7A have been 49 
reported, mostly substitutions and deletions (ATP7A database, www.LOVD.nl/ATP7A) 50 
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which lead to misfolding (65), impaired copper-induced trafficking (66) or reduced copper-1 
ATPase activity (67). 2 
 3 
4.1.2. ATP7B 4 
 5 
WD is an autosomal recessive disorder caused by mutations in ATP7B (60), a copper-ATPase 6 
which is mainly expressed in liver and implicated in biliary copper excretion (61). ATP7B 7 
dysfunction results in the toxic buildup of copper in liver. Brain copper accumulation 8 
develops secondary to liver disease and leads to degeneration of the basal ganglia. As a 9 
consequence, WD patients present movement disorders such as tremor, dystonia and 10 
parkinsonism (68).  11 
 12 
A number of single nucleotide polymorphisms in ATP7B are associated with an increased 13 
risk of AD (69). Furthermore, it has been suggested that a single mutated ATP7B allele may 14 
confer susceptibility for (late-onset) parkinsonism (70). 15 
 16 
4.2. P2-type ATPases in neurological disorders 17 
 18 
The P2-type ATPases constitute the best characterized subfamily of P-type ATPases. The 19 
human P2 isoforms can be subdivided into three groups, P2A, P2B
 
and P2C (P2D
 
is not 20 
represented in humans, but consists of eukaryotic Na
+
-ATPases). The P2A group contains the 21 
well-known SERCA and Secretory Pathway/Golgi (SPCA) Ca
2+
-ATPases, whereas the 22 
plasma membrane Ca
2+
-ATPases (PMCAs) belong to the P2B-ATPases. The P2C-subgroup 23 
encompasses the Na
+
/K
+
-ATPases and the gastric H
+
/K
+
-pumps (33, 34). 24 
 25 
4.2.1. Na
+
/K
+
-ATPase  26 
 27 
The Na
+
/K
+
-ATPase generates vital Na
+
 and K
+
 gradients over the plasma membrane by 28 
expelling three Na
+
 ions in exchange for two K
+
 ions. This is essential for many physiological 29 
functions in the nervous system such as cell volume control, the drive of secondary active 30 
transport systems and the support of electrical excitability (reviewed in (71)). The α-subunit is 31 
the catalytical subunit of the Na
+
/K
+
-ATPase that exists in four isoforms (ATP1A1-4 or α1-4), 32 
which display tissue specific and developmental dependent expression. Only the ATP1A1-3 33 
genes are expressed in the nervous system. The α-subunit forms a hetero-oligomer with a β- 34 
and γ-subunit. β is critical for proper targeting and affects the K+ affinity (72), whereas γ 35 
(belonging to the FXYD family) mainly regulates the Na
+ affinity of the pump (73).  36 
 37 
The neurological disorders familial hemiplegic migraine type 2 (FHM2), alternating 38 
hemiplegia of childhood (AHC), and rapid-onset dystonia parkinsonism (RDP) are autosomal 39 
dominant disorders caused by mutations of the Na
+
/K
+
-ATPase α2 (FHM2 and AHC1) and α3 40 
(AHC2 and RDP) isoforms. α2 (ATP1A2) is primarily expressed in astrocytes and drives 41 
Na
+
-dependent Glu uptake and removes excess K
+
 from the extracellular space during 42 
neuronal excitation. α3 (ATP1A3) is predominantly expressed in neurons and is involved in 43 
post-stimulus recovery (reviewed in (74)).  44 
 45 
4.2.1.1. ATP1A2  46 
 47 
ATP1A2 mutations lead to FHM2, a severe subtype of migraine with aura and temporary 48 
hemiparesis. More than 20 mutations in the α2-subunit are known to cause FHM2 (75-77). A 49 
disturbed clearance of extracellular K
+
 by glial cells underlies FHM2, which is related to an 50 
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impaired pumping rate (77). ATP1A2 mutations may also underlie basilar migraine (BM), 1 
which is a subtype of migraine with aura originating from the brainstem or involvement of 2 
both hemispheres (78). In addition, a mutation in the ATP1A2 gene was also identified in 3 
affected members of a family with AHC1 (79). FHM2, BM and AHC1 are allelic disorders 4 
with overlapping phenotypes. 5 
 6 
4.2.1.2. ATP1A3  7 
 8 
Mutations in ATP1A3 (also known as dystonia-12, DYT12) lead to RDP, which is a rare 9 
autosomal dominant movement disorder with variable penetrance, characterized by the abrupt 10 
start of dystonia with signs of parkinsonism (80). The onset of RDP (at the age of 4-55) is 11 
often triggered by physical or emotional stress, fever, childbirth or alcohol consumption. 12 
RDP-associated mutations are predominantly located in highly conserved residues in the TM 13 
domain of ATP1A3, which mainly affect the Na
+
 affinity (81, 82). The resulting intracellular 14 
Na
+
 increase may possibly affect the Na
+
/Ca
2+
 exchange system and subsequently lead to 15 
increased intracellular Ca
2+
 impacting on Ca
2+
-dependent signaling pathways, such as 16 
neurotransmitter release (81). Mutations in ATP1A3 are also implicated in AHC2 (83), which 17 
generally has earlier onset than RDP and is characterized by transient episodes of hemiplegia 18 
often shifting from one side of the body to the other. AHC2 and RDP present overlapping 19 
clinical features such as dystonia with a bulbar preference (74, 83).  20 
 21 
According to the crystal structure of Na
+
/K
+
-ATPase, the C-terminal tail is inserted within a 22 
binding pocket between TM helices (41). This tail controls Na
+
 and proton binding at the third 23 
Na
+
 site. At least eight disease mutations occur in this C-terminal ion pathway (84). Two 24 
disease mutations have been reported in which the C terminus is extended by one Tyr residue 25 
in a patient with RDP (82) and by a 28-residue long segment in a patient with FHM2 (76).  26 
 27 
4.2.2. ATP2B3 28 
 29 
PMCA isoforms (ATP2B1-4) remove Ca
2+
 from the cytosol to the extracellular environment. 30 
ATP2B3 mutations cause early onset X-linked spinocerebellar ataxia-1, a disorder 31 
characterized by degeneration of the cerebellum (85). Clinical manifestations include 32 
hypotonia at birth, dysarthria, gait ataxia difficulty standing, slow eye movements and 33 
delayed motor development. PMCA3 is highly expressed in the cerebellum, a critical region 34 
for motor coordination (85). 35 
 36 
4.3. P4-type ATPases in neurological disorders 37 
 38 
The human genome encodes 14 P4-type ATPases, which are putative lipid flippases involved 39 
in aminophospholipid transport across membrane bilayers. P4-type ATPases are the first class 40 
of P-type transporters that do not transport inorganic ions (reviewed in (86-88)).  41 
 42 
4.3.1. ATP8A2 43 
 44 
The P4-type ATPase ATP8A2 is a phosphatidylserine (PS) translocase, which is localized to 45 
the plasma membrane and highly expressed in retina and brain, particularly in the cerebellum. 46 
The P4 lipid flippase ATP8A2 is involved in localization of PS to the inner leaflet of the 47 
plasma membrane (89). A missense mutation located in a M domain of ATP8A2 is associated 48 
with cerebellar ataxia, mental retardation and dysequilibrium syndrome (CAMRQ), an 49 
autosomal recessive disorder characterized by dysarthric speech and cerebellar atrophy with 50 
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or without quadrupedal gait (90). Mice carrying loss-of-function mutations in the Atp8a2 gene 1 
develop axonal degeneration resulting in progressive ataxia and neurodegeneration (89). Loss 2 
of ATP8A2 disrupts PS asymmetry which might lead to fragile neuronal membranes that are 3 
more prone to degeneration. Defective vesicular trafficking may provide an alternative 4 
explanation (89). 5 
 6 
4.3.2. ATP10A 7 
 8 
ATP10A is a putative aminophospholipid translocase. ATP10A maps within the most 9 
common interval of deletion (15q11-q13) leading to Angelman syndrome (AS). This 10 
syndrome is marked by neurobehavioral anomalies that include severe mental retardation, 11 
ataxia and epilepsy. AS patients with imprinting mutations or with maternal deletions of 12 
15q11−q13 display little or no ATP10A expression (91).  13 
 14 
4.4. P5-type ATPases in neurological disorders 15 
 16 
Two members of the P5-type ATPases are implicated in neurological disorders. Little is 17 
known about the substrate specificity and cellular function of P5-type ATPases, but their 18 
putative function is extensively discussed in section 5 of this review. 19 
 20 
4.4.1. ATP13A2 21 
 22 
Loss-of-function mutations in ATP13A2 (PARK9) are a known cause of Kufor-Rakeb 23 
syndrome (KRS), an autosomal recessive disorder characterized by juvenile-onset 24 
Parkinsonism associated with dementia (25). This syndrome was first described in 1994 in a 25 
consanguineous family originating from Kufor-Rakeb, Jordan (92). Today, several 26 
homozygous and compound heterozygous mutations have been described that result in 27 
truncation of the ATP13A2 protein leading to loss-of-function (25, 93-95). The clinical 28 
phenotype of KRS comprises pyramidal degeneration, supranuclear gaze palsy and severe 29 
cognitive decline (96). Brain MRI of KRS patients revealed generalized atrophy and 30 
putaminal and caudate iron accumulation, classifying KRS amongst neurodegeneration with 31 
brain iron accumulation (93, 97), although others reported KRS patients without iron 32 
accumulation (98). KRS can be classified as a complex dystonia, i.e. a form of dystonia that 33 
occurs in conjunction with other neurological or non-neurological symptoms (99, 100).  34 
 35 
Whereas wild-type ATP13A2 is localized to late endosomal and lysosomal membranes (25), 36 
the truncating KRS mutations lead to retention of the protein in the ER resulting in ER stress 37 
and proteasomal degradation via the ER-associated degradation pathway (101). Other 38 
missense mutations in ATP13A2 have been identified that are associated with early-onset 39 
Parkinsonism (102-105). Similar to KRS mutations, homozygous missense mutations disrupt 40 
normal localization and function of ATP13A2 while heterozygous missense mutations may 41 
impair ATPase activity (106). Moreover, ATP13A2 protein levels are increased in surviving 42 
neurons of humans with PD/dementia with LBs indicative of a putative protective function of 43 
high levels of ATP13A2. In LBs positive neurons ATP13A2 did not co-localize directly, but 44 
rather surrounds the LBs (107).  45 
 46 
In dogs (32, 108) and mice (31), loss of ATP13A2 elicits neuronal ceroid lipofuscinosis 47 
(NCL), a lysosomal storage disorder characterized by the accumulation of autofluorescent 48 
lipopigment. The phenotype of NCL partially overlaps with that of KRS and involves 49 
dysarthria, cerebellar ataxia, rigidity, bradykinesia and cognitive impairment. Atp13a2 50 
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deficient mice exhibit age-dependent sensorimotor deficits that resemble motor symptoms 1 
observed in KRS, NCL and PD patients. Moreover, loss of Atp13a2 leads to lipofuscin 2 
accumulation and α-synuclein aggregation in the hippocampus, critical features of NCL and 3 
PD, respectively (31). Also a homozygous ATP13A2 missense mutation was reported that is 4 
associated with juvenile NCL in humans (30). Extensive lipofuscinosis was demonstrated in 5 
neuronal and glial cells of cortex, basal ganglia and cerebellum (30). These findings underline 6 
the importance of ATP13A2 in the lysosomal pathway for α-synuclein degradation and 7 
suggest that lysosomal dysfunction might represent a link between lipofuscinosis and α-8 
synuclein accumulation. 9 
 10 
4.4.2. ATP13A4 11 
 12 
ATP13A4 has been linked to language delay (54, 109) and autism spectrum disorders (ASD) 13 
(110). In two patients, disruption of ATP13A4 led to specific language impairment 14 
characterized by delayed expressive and receptive language, without further cognitive 15 
deficiencies (54). Moreover, in a Finnish genome-wide screen for ASD, an autism 16 
susceptibility locus was identified on chromosome 3q25-27, nearby ATP13A4 (111). In six 17 
study participants, a Glu646Asp sequence variant was found, which is located between the 18 
fourth and fifth TM region of ATP13A4, near the conserved Asp residue and the N-domain 19 
(54). 20 
  21 
There is very little knowledge concerning the biological role of ATP13A4. In mice, Atp13a4 22 
is mainly expressed in stomach and brain (112). Atp13a4 expression varies throughout all 23 
regions of the adult mouse brain, with the highest relative expression in cerebellum. Atp13a4 24 
expression is also developmentally regulated, peaking at late neurogenesis, suggesting a 25 
function in neuronal development (110, 113). In humans, ATP13A4 mRNA has been detected 26 
in multiple organs, with relatively low expression in the brain, where expression was 27 
observed in the lateral inferior frontal cortex (Broca’s area) and the temporoparietal cortex 28 
(Wernicke’s area) (54), areas of importance for language output and input, respectively. 29 
ATP13A4 is observed in the ER membrane and increases intracellular Ca
2+
 levels when 30 
overexpressed in COS-7 cells (110). The intracellular Ca
2+
 increase is not observed in cells 31 
overexpressing the Glu646Asp variant, implying that the substitution might impair the ability 32 
of ATP13A4 to regulate Ca
2+
 transport (110). 33 
 34 
5. Cellular function of P5B ATPases in model organisms 35 
 36 
A major bottleneck in unraveling the role of ATP13A2 in neurological disorders is the fact 37 
that virtually nothing is known concerning the molecular function and substrate specificity of 38 
the P5B-type ATPases. In this section, we will discuss the cellular role of ATP13A2 39 
orthologues in different model organisms.  40 
  41 
5.1. YPK9 in the yeast Saccharomyces cerevisiae  42 
 43 
Ypk9p (yeast PARK9), is the single P5B-type ATPase in the yeast Saccharomyces cerevisiae 44 
and resides in the vacuolar membrane, the yeast equivalent of the mammalian lysosome (29). 45 
Studies in yeast show that Ypk9p is involved in protecting cells against Mn
2+
 toxicity (29) 46 
and, more broadly, heavy metals (114-116), but the ion specificity might be strain dependent 47 
(114). Little or no other phenotypes have been reported. According to the S. cerevisiae 48 
genome database (http://yeastgenome.org) 74 genes or gene products have been reported as 49 
interactors of YPK9. Most interactions are genetic (72 in total) highlighting genes that when 50 
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deleted in the absence of YPK9 result in synthetic growth effects or phenotypic suppression or 1 
enhancement (Fig. 5). Supplemental Table 1 integrates data on interactions from high- and 2 
low-throughput studies in yeast available at BioGrid (http://thebiogrid.org). The interactors 3 
vary both with respect to cellular location and predicted function. Surprisingly, only a few of 4 
the interactors are located in the endosome and vacuolar systems (6 out of 74 interactors). The 5 
most prevalent interactions participate in vesicular trafficking and protein sorting (12 out of 6 
74 interactors) and transcriptional flux (11 out of 74) (Fig. 5). 7 
 8 
Only one gene, TATA-binding protein-associated factor-1, TAF1, has so far been reported to 9 
be synthetic lethal in combination with deletion of YPK9. TAF1 encodes the largest 10 
transcription factor TFIID subunit involved in RNA pol II transcription initiation, promoter 11 
binding and G1/S progression (117). Taf1p relocalizes to the cytosol in response to hypoxia, 12 
whereas subsequent oxygen exposure restores the nuclear localization (118). Also the 13 
expression of ATP13A2 in mammalian cells is upregulated in conditions of hypoxia (119). In 14 
humans, TAF1 is associated with complex dystonia (X-linked parkinsonism, unconfirmed 15 
genetic evidence) (120) (reviewed in (99, 100). This might suggest a putative link between 16 
ATP13A2 and TAF1 in humans. Human TAF1 possesses protein kinase, ubiquitin-activating 17 
and -conjugating activities and histone acetyltransferase activities. These activities control 18 
transcription of genes involved in the G1 progression in mammalian cells such as cyclin D1 19 
and cyclin A (121). 20 
 21 
OPI3 and YME1 are so far the only two positive genetic interactors that have been identified. 22 
Thus, deletion of any of these genes in combination with a deletion of YPK9 alleviates growth 23 
effects caused by loss of either. OPI3 encodes the methylene-fatty-acyl-phospholipid 24 
synthase, which catalyzes the last two steps in phosphatidylcholine biosynthesis at the ER 25 
membrane in contact zones with the plasma membrane (122). YME1 encodes the catalytic 26 
subunit of the i-AAA protease complex that is responsible for degradation of unfolded 27 
mitochondrial proteins in the intermembrane space. Yme1p mediates Atg32p processing, 28 
which is required for mitophagy (123). It also contributes substantially to the proteolytic 29 
turnover of phosphatidylserine decarboxylase-1 (PSD1) located at the mitochondrial inner 30 
membrane (124).  31 
 32 
The link between YPK9 and the mitochondria is further underscored by negative genetic 33 
interactions with six other genes (ATP5, MDL2, MMM1, FMT1, GEP3 and OXR1) that 34 
encode proteins related to mitochondrial function. Negative interactions are defined as genes 35 
that upon deletion, in combination with a YPK9 deletion, display aggravated growth effects as 36 
compared to the loss of either individual gene. The six genes are related to maintenance of 37 
mitochondrial homeostasis (ATP5, MDL2, MMM1), mitochondrial biogenesis (FMT1, GEP3) 38 
and resistance to oxidative damage (OXR1). Several interactors of YPK9 can thus be related to 39 
mitochondrial function, which substantiates a link between YPK9 and protection from 40 
oxidative stress.  41 
 42 
The remaining majority of interactors related to YPK9 have been identified in a genome-wide 43 
screen aimed at defining mechanisms by which YPK9 protects cells from Mn
2+
 toxicity in 44 
yeast (115). At physiological conditions, YPK9 genetically interacts with essential genes 45 
involved in the cell cycle (APC5, CDC28, CDC53, SFH1, POL3, CDC11 and CDC12), 46 
cellular transport and vesicular trafficking (ALG1, GAB1, BET2 and MYO2) or RNA 47 
processing (DIM1). Cdc11p and Cdc12p belong to the septin family, which includes highly 48 
conserved GTP-binding proteins found in eukaryotes. Septins provide a scaffold to support 49 
cell division, polarity and compartmentalization and have been implicated in diverse 50 
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neurodegenerative disorders in humans, including in PD and α-synuclein mediated toxicity 1 
(125). BET2 encodes the beta subunit of type II geranylgeranyl transferase (126) that is 2 
required for vesicular transport between the ER and the Golgi (127). Bet2p provides a 3 
membrane anchor to the Rab-like protein Ypt1p, which like Ypk9p, protects yeast cells from 4 
α-synuclein toxicity (128).  5 
 6 
Yeast genes involved in Mn
2+
 protection mainly belong to categories of vesicle-mediated 7 
transport, vacuolar organization and chromatin remodeling (115). YPK9 deletion modifies 8 
Mn
2+
 tolerance of a subset of these genes. Interactors that increase Mn
2+
 sensitivity of YPK9 9 
are implicated in vacuolar and vesicle organization and membrane fusion (such as VAM3, 10 
VAM6, SWF1 and GLO3), whereas interactors that increase Mn
2+
 tolerance (such as SIF2, 11 
HMO1, LEO1, APQ12 and MOG1) seem to be involved in chromatin organization, histone 12 
modification and nuclear transport (115). However, it is unclear why none of the established 13 
Mn
2+
 or heavy metal transport systems have been reported to be genetically linked to YPK9. 14 
This could be because YPK9 is located upstream of established transport systems that take 15 
care of Mn
2+
 clearance. Ypk9p might for instance be implicated in the regulation of vesicular 16 
transport routes that control Mn
2+
 homeostasis. As Mn
2+
 ions are redox active Ypk9p may 17 
also regulate the removal pathway of damaged mitochondria via autophagy.  18 
 19 
Taken together, the genetic interaction data from yeast suggest a potential role for YPK9 in 20 
the cell cycle and vesicular trafficking in combination with proper mitochondrial function. 21 
 22 
5.2 Animal models of ATP13A2 23 
 24 
C. elegans – C. elegans contains three P5B genes, catp-5 to 7. In contrast to the 25 
vacuolar/lysosomal localization of other P5B ATPases, CATP-5 locates to the plasma 26 
membrane at the apical side of intestinal cells (129). catp-5 mutant strains are impaired in 27 
polyamine uptake (129). Polyamines are ubiquitous cellular components that affect numerous 28 
biological processes such as cell cycle progression. Polyamines interact with anionic binding 29 
sites of macromolecules such as nucleic acids and phospholipids. catp-5 might either encode a 30 
polyamine transporter or the gene might positively regulate polyamine uptake (129). In 31 
mammalian CHO cells, ATP13A2 overexpression leads to a two-fold higher accumulation of 32 
the polyamine spermidine. It was shown that the ATP-dependent spermidine uptake was 33 
increased in a lysosomal and late endosomal fraction further supporting the notion that the 34 
ATP13A2 protein mediates polyamine uptake (130). The higher polyamine uptake rate might 35 
further explain the increased cytotoxic effects of paraquat, a toxic polyamine analogue that is 36 
an environmental risk factor for PD (131).  37 
 38 
CATP-6 locates depending on the tissue type to either cytoplasmic punctae likely 39 
corresponding to vesicles associated with the lysosome or to the plasma membrane (132). 40 
catp-6, was identified in a RNAi screen for genes stabilizing synthetic α-synuclein, 41 
representing a putative functional homologue of ATP13A2 (133). The catp-6 locus 42 
genetically interacts with gon-2 and gem-1 (132). gon-2 encodes a TRPM cation channel 43 
protein that is required for Mg
2+
 uptake, whereas gem-1 encodes for the SLC16A transporter, 44 
which might be a putative monocarboxylate transporter. It was suggested that the catp-6 gene 45 
product governs Mg
2+
 uptake by regulating the trafficking of transporters or other regulatory 46 
proteins to the plasma membrane (132). 47 
 48 
Mouse – The phenotype of a genetic knock-out mouse model of Atp13a2 was recently 49 
described (31). The insertion site of the Neo gene in the genome of the Atp13a2
-/-
 mice would 50 
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still allow the formation of a truncated and mutated N-terminal Atp13a2 fragment consisting 1 
of the first 341 amino acids of Atp13a2 followed by 168 unrelated amino acids. Although the 2 
mutated transcript is clearly formed, no traces of the mutated protein were detected, 3 
suggesting that it may either be unstable or inefficiently translated (31).  4 
 5 
As mentioned above, the Atp13a2
-/-
 mice show α-synuclein accumulation as occurs in PD and 6 
related synucleinopathies, and accumulation of lipofuscin deposits, characteristic of NCL 7 
(31). The α-synuclein aggregation occurred predominantly in the hippocampus, but not in the 8 
cortex or cerebellum. Also the expression of some genes involved in PD is altered between 9 
the striatum and substantia nigra in Atp13a2
-/-
 versus Atp13a2
+/+
 mice (31). 10 
 11 
20-29 months old Atp13a2
-/-
 mice perform more poorly on several sensorimotor tests. More 12 
specifically, the aged Atp13a2
-/-
 mice display impaired aspects of motor learning. The gait 13 
analysis revealed a shortened stride length. Also reduced hindlimb stepping, impairments in 14 
fine motor skills and orofacial movements involved in nest building were reported (31). These 15 
deficits are similar to those observed in other genetic mouse models of PD and ataxia and also 16 
resemble aspects of motor dysfunction observed in KRS, NCL and PD (31). Cognitive 17 
function and emotional reactivity were also changed in Atp13a2
-/-
 mice. Mutant mice 18 
demonstrated greater exploratory behavior without changes in general locomotor activity or 19 
anxiety. Because the behavioral phenotype was not detectable until old age, some 20 
compensatory mechanisms might take place, which might be related to other members of the 21 
P5-ATPase family. But so far, no evidence was found for a compensatory upregulation of 22 
other P5-type ATPases (31). 23 
 24 
Zebra fish – In contrast, knocking out ATP13A2 in the zebra fish results in severe retardation 25 
already at the embryonic stage of development (134). As the mouse genome contains four 26 
P5B genes (Atp13a2-5), while the zebra fish only one (ATP13A2), the late-onset mouse 27 
phenotype associated with loss of ATP13A2 would suggest that some of the P5B homologues 28 
in mice may be functionally redundant, possibly compensating for each other’s loss (31). 29 
Further studies will be required to shed light on the possible redundancy of P5B function and 30 
whether compensatory effects from other P5 alleles can take place. 31 
 32 
 33 
6. Cellular roles of human ATP13A2 34 
 35 
6.1. ATP13A2 expression profile 36 
 37 
ATP13A2 is mapped to the PARK9 PD susceptibility locus on chromosome 1p36. ATP13A2 38 
is predominantly expressed in the brain, particularly in the dopaminergic neurons of the 39 
substantia nigra (25). Studies in mouse have shown that Atp13a1 (P5A) and Atp13a2 (P5B) 40 
are broadly expressed in many tissues with the highest expression of Atp13a2 observed in the 41 
brain. Atp13a4 and Atp13a5 (both P5B) are only expressed in brain and stomach while 42 
Atp13a3 (P5B) has a wider expression pattern that includes brain and other internal organs 43 
like colon, kidney and liver (112). It thus seems that all P5-type ATPase isoforms are 44 
expressed in the brain although individual members express at different levels during various 45 
developmental stages. Expression of Atp13a2 peaks during neurogenesis while Atp13a5 46 
peaks at the adult stage (113). These observations are in line with a significant, yet 47 
undescribed role for P5B ATPases in brain development and function.  48 
 49 
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At least three ATP13A2 splice variants are reported (101). Variant 1 is the longest and counts 1 
1180 amino acids. Variant 2 contains a five amino acid in-frame deletion in the N-terminus 2 
(1175 amino acids), whereas variant 3 is 1158 amino acids long and appears to be an 3 
anomalous protein. Here, the last two TM helices are replaced by an unusual sequence stretch 4 
and variant 3 also lacks an important part of the connection of the TM region with the 5 
cytosolic domains. Based on comparison with other P-type ATPases these alterations will 6 
probably have a significant impact on enzymatic activity. Variant 3 is retained in the ER and 7 
is rapidly degraded, questioning whether it serves a cellular role (101). 8 
 9 
The promoter region of the human ATP13A2 gene contains hypoxia response elements, 10 
which can bind to the transcription factor hypoxia inducible factor 1a (HIF-1a). Hypoxic 11 
conditions up-regulate transcription of the ATP13A2 gene in both HEK293 and dopaminergic 12 
MN9D cells (119). Also Mn
2+
 and Zn
2+
 elevate ATP13A2 expression in several cell lines (see 13 
further details below) (27, 135). 14 
 15 
6.2 Intracellular localization of ATP13A2 16 
 17 
The general accepted view is that ATP13A2 is targeted to acidic compartments, i.e. the late 18 
endosomes and lysosomes, because of a co-localization with LAMP1/2a, Rab7 and 19 
Lysotracker. Also the loss of ATP13A2 leads to lysosomal dysfunction and an increase in the 20 
size and number of the lysosomes (26, 28). Originally, it was suggested that ATP13A2 is 21 
localized to late endosomes/lysosomes based on overexpression studies of tagged ATP13A2 22 
(25). However, this view was recently challenged (116). In both differentiated SHSY5Y cells 23 
and rat primary neurons, the endogenous ATP13A2 associates closely together with LC3, a 24 
marker of the autophagosomes. More specifically, the authors concluded that the endogenous 25 
ATP13A2 occupies the outer limiting membrane of multivesicular bodies (MVBs), a 26 
morphologically distinctive late endosome compartment. MVBs undergo dynamic 27 
rearrangements and sorting of lipids and proteins via inward budding of the membrane 28 
generating multiple intra-luminal vesicles (ILVs). By fusing with the plasma membrane, 29 
MVBs can release the ILVs in the extracellular space as exosomes. MVBs can also fuse with 30 
autophagosomes from autophagy pathways producing hybrid structures referred to as 31 
amphisomes, which then can fuse with lysosomes for cargo degradation. ATP13A2 is also 32 
observed in the outer membrane of amphisomes (116).  33 
 34 
6.3. ATP13A2 is involved in autophagy and mitochondrial clearance 35 
 36 
Mitochondrial dysfunction is tightly linked to the pathogenesis of PD (6, 23, 136). Strong 37 
support comes from the observations that 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine 38 
(MPTP), a potent mitochondrial complex I inhibitor, triggers a PD-like syndrome (137, 138). 39 
Several PD-associated genes, namely parkin, PINK1 and DJ-1 play a role in mitochondrial 40 
dynamics and clearance strengthening the concept that mitochondrial dysfunction and the 41 
production of ROS are consistent features of PD (6, 23). Thus, clearance of dysfunctional or 42 
damaged mitochondria and misfolded proteins is essential for neuronal fitness and survival 43 
(23, 136) and the lysosome is a vital organelle for this quality control (21, 23, 139). 44 
Organelles, cytoplasmic material and protein aggregates are delivered to the lysosome via 45 
various autophagy pathways. Macroautophagy (or just autophagy) involves the formation of 46 
double-layered membrane autophagosomes, which encapsulate cytoplasmic materials for 47 
delivery to the lysosomes for degradation. Mitochondria are removed through a specific 48 
autophagy pathway called mitophagy (23). Soluble proteins can also be selectively degraded 49 
in the lysosome through uptake by the lysosomal receptor LAMP2a, via a process known as 50 
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chaperone-mediated autophagy (CMA) (24). Micro-autophagy involves the direct engulfment 1 
of cytoplasmic material by invagination of the late endosomal/lysosomal membrane. Whereas 2 
the function of micro-autophagy in mammalian cells is unknown, both macro-autophagy and 3 
CMA are key processes in neurodegeneration and α-synuclein removal (17, 24) (reviewed in 4 
(140)).  5 
 6 
Studies in KRS patient-derived fibroblasts and ATP13A2-deficient cell lines have revealed 7 
that mutations of ATP13A2 or knockdown of the gene transcript lead to several lysosomal 8 
alterations. First the number and size of lysosomes is increased (28). Also lysosomal 9 
dysfunction is reported involving impaired lysosomal acidification, decreased proteolytic 10 
processing of lysosomal enzymes, reduced degradation of lysosomal substrates (e.g. α-11 
synuclein) and impaired lysosomal-mediated clearance of autophagosomes (26-28).  12 
 13 
In parallel, a strong link between ATP13A2 and mitochondrial dysfunction is emerging. Loss 14 
of ATP13A2 function impairs mitochondrial maintenance and leads to oxidative stress. 15 
ATP13A2 expression protects mammalian cells towards mitochondrial and oxidative stress 16 
(141). In fibroblasts of patients with non-functional ATP13A2 ATP production rates are 17 
decreased. Also a higher frequency of mitochondrial DNA lesions, increased oxygen 18 
consumption rates and increased fragmentation of the mitochondrial network have been 19 
observed (142).  20 
 21 
A role for ATP13A2 in autophagy and mitochondrial clearance has been suggested, but 22 
mechanistic details are lacking (142-144). ATP13A2 regulates mitochondrial bioenergetics 23 
through macroautophagy. ATP13A2 knockdown reduces the autophagic flux in SHSY5Y 24 
cells (144) and lysosomal-mediated clearance of autophagosomes was impaired in patient-25 
derived ATP13A2
-/-
 fibroblasts (26) and in ATP13A2 knockdown neurons (28). Several 26 
physical interactors of ATP13A2 are involved in mitophagy whereas others are involved in 27 
protein quality, protein sorting, vesicular transport and membrane fusion (145). Evidence 28 
from genetic interaction studies in yeast also provides a link between YPK9 and mitochondrial 29 
clearance (see above). 30 
 31 
The fact that ATP13A2 expression is upregulated under oxidative stress (119) seems to 32 
indicate that ATP13A2 is particularly important in conditions of oxidative stress, for instance 33 
arising from mitochondrial dysfunction. Defective mitochondrial clearance may also account 34 
for the increased sensitivity towards Zn
2+
 toxicity in ATP13A2
-/-
 cells (143). Indeed, Zn
2+
 35 
induces mitochondrial ROS production, which results in mitochondrial dysfunction and 36 
fragmentation (143). Importantly, treatment with an antioxidant completely abolishes Zn
2+
-37 
induced cell death in ATP13A2
-/-
 cells (143). The link between Zn
2+
 and mitochondrial stress 38 
is further emphasized by the observation that Zn
2+
 potentiates, whereas Zn
2+
 chelation 39 
protects against MPTP-induced PD (146). Along the same lines, loss of ATP13A2 and 40 
impaired mitochondrial clearance may explain the observed intolerance towards Mn
2+
 (29, 41 
114) and paraquat (131). Since polyamines can function as ROS scavengers, the increased 42 
uptake of polyamines (130) may protect ATP13A2
-/-
 cells towards oxidative stress, although 43 
high levels of polyamines are also toxic.  44 
 45 
Together, these observations suggest that ATP13A2 controls mitochondrial maintenance, 46 
which would lend further support to converging lysosomal and mitochondrial pathways in PD 47 
pathogenesis (21, 23, 139). By controlling the autophagy-lysosomal activity ATP13A2 may 48 
serve an essential function by removing damaged or dysfunctional proteins and organelles. 49 
 50 
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6.4. ATP13A2 is involved in vesicular transport  1 
 2 
The long list of putative physical interactors (145) points into the direction of ATP13A2 as a 3 
scaffolding protein in the regulation of vesicular processes. Like other P-type ATPases, such 4 
as the Na
+
/K
+
-ATPase (147) and the SERCA2 Ca
2+
-ATPase (148), ATP13A2 might be acting 5 
as a scaffold and exert a transporting function at the same time. Regulation of vesicular 6 
processes may include de novo vesicle formation, vesicular transport, vesicular sorting 7 
mechanisms and vesicle fusion. E.g. ATP13A2 directly interacts with several components of 8 
the SNARE complex that is involved in vesicle docking and fusion (145). A function in 9 
vesicular transport can be easily reconciled with the established roles of ATP13A2 in 10 
mitochondrial clearance (143, 144) and α-synuclein removal (29, 116), which depend on 11 
autophagy pathways. In addition, ATP13A2 controls vesicle-dependent Zn
2+
 and α-synuclein 12 
removal mechanisms through exosomes, which are ILVs formed in the MVBs that fuse with 13 
the plasma membrane (116). Genetic evidence in yeast also provides a link between YPK9 14 
and vesicular transport (see above). 15 
 16 
6.5. The connection between ATP13A2 and α-synuclein 17 
 18 
ATP13A2 protects cells towards α-synuclein toxicity. This has been observed in several 19 
model systems including yeast, C. elegans and mammalian cells (29). Like α-synuclein, 20 
ATP13A2 might be implicated in vesicle trafficking and mitochondrial dysfunction. Several 21 
hypotheses may explain the protective effect of ATP13A2.  22 
 23 
(a) By regulating lysosomal functions ATP13A2 might control lysosomal α-synuclein 24 
degradation and prevent the build-up of α-synuclein aggregates (26-28). 25 
(b) Alternatively, ATP13A2 may control the delivery of α-synuclein to the lysosomes by 26 
regulating different autophagy pathways such as macro-autophagy (26, 28) and chaperone-27 
mediated autophagy, two autophagic routes that control α-synuclein turnover (17, 24).  28 
(c) α-synuclein may prevent the membrane fusion of the mitochondria resulting in increased 29 
mitochondrial fragmentation (149). α-synuclein also impairs mitochondrial function (6). The 30 
protective effect of ATP13A2 towards α-synuclein toxicity might therefore be related to the 31 
positive effect of ATP13A2 on mitochondrial appearance (142-144), which might compensate 32 
excessive mitochondrial fragmentation. One can speculate that via promotion of 33 
mitochondrial clearance, ATP13A2 might provide protection towards α-synuclein-induced 34 
mitochondrial fragmentation.  35 
(d) ATP13A2 promotes the removal of α-synuclein out of the cell via exosomes reducing the 36 
α-synuclein stress in cells (116).  37 
(e) As α-synuclein interacts with membranes and the amount of α-synuclein interaction with 38 
the membrane seems to correlate with the degree of toxicity (6, 150), it is a tempting 39 
hypothesis that ATP13A2 might affect α-synuclein membrane interactions.  40 
 41 
6.6. ATP13A2 controls cellular ion homeostasis 42 
 43 
ATP13A2 causes protection towards several heavy metals (29, 114, 116) and in KRS patients 44 
iron deposits in the brain are observed (93, 97). The prevailing hypothesis is therefore that 45 
ATP13A2 is a lysosomal cation pump (29). This hypothesis is furthermore based on sequence 46 
similarity with other P-type ATPases (25), among which most transport cations, e.g. to 47 
generate vital electrochemical ion gradients, to relocalize essential elements or dispose toxic 48 
metal ions. 49 
 50 
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7. What is the transported ligand – if any – of ATP13A2? 1 
 2 
Although P5B ATPases have essentially all sequence requirements to act as transporters, their 3 
ligands so far remain unidentified. ATP13A2 may regulate lysosomal function by transporting 4 
ions (29) or an essential co-factor required for lysosomal enzyme activity (141). ATP13A2 5 
might also take up metal ions in lysosomes or MVBs/exosomes to remove excess ions (116). 6 
The possibility that ATP13A2 works closely together with the V-type ATPases to pump 7 
protons to contribute to the low pH in the late endosome/lysosome can also not be excluded 8 
(26). In this section we will critically review the prevalent concept that ATP13A2 is a cation 9 
transporter by comparing sequence characteristics of ATP13A2 with better described P-type 10 
ion pumps and discussing the available physiological and biochemical evidence for transport 11 
of proposed ligands. Finally, we discuss the possibility that ATP13A2 might pump organic 12 
ions, such as lipids or peptides from one membrane leaflet to the other. 13 
 14 
7.2. Cation(s) possibly transported by ATP13A2 15 
 16 
ATP13A2 has been linked to Mn
2+
, Zn
2+
, Mg
2+
 and H
+
 homeostasis suggesting that ATP13A2 17 
might be implicated in the transport of these cations. 18 
 19 
7.2.1. Is ATP13A2 a Mn
2+
 transporter? 20 
 21 
ATP13A2 was first suggested to be a lysosomal Mn
2+
 transporter (29). Mn
2+
 is a biologically 22 
relevant metal that functions as a cofactor of many enzymes, such as carboxylases and 23 
phosphatases in the cytosol, sugar transferases and sulfatases in the Golgi and the 24 
mitochondrial superoxide dismutase SOD2 (151, 152). Little is known about Mn
2+
 25 
requirements in lysosomes or MVBs, but Mn
2+
 uptake in the MVBs and lysosome could 26 
constitute a Mn
2+
 detoxification pathway to remove excessive Mn
2+
. This would prevent Mn
2+
 27 
toxicity, which evokes extrapyramidal syndromes resembling PD and dystonia (151, 152). 28 
Mn
2+
-induced cell death involves oxidative stress, interference with Ca
2+
 and iron 29 
homeostasis, DNA damage and mitochondrial dysfunction (135). It is thus clear that Mn
2+
 30 
levels need to be properly controlled, but the responsible pathways remain incompletely 31 
understood. 32 
 33 
A role of ATP13A2 in Mn
2+
 homeostasis and Mn
2+
 toxicity has been proposed based on the 34 
following observations. Loss of YPK9 in yeast leads to an increased sensitivity towards Mn
2+
 35 
(29, 114), whereas mammalian cells (HEK293, Neuro2a and NLF neuroblastoma cells) that 36 
overexpress ATP13A2 showed resistance to MnCl2-induced cytotoxicity (135, 141). Atomic 37 
absorption spectrophotometry further revealed that HEK293 cells overexpressing ATP13A2 38 
accumulate less Mn
2+ 
when cells were pre-exposed to MnCl2. Also the endogenous ATP13A2 39 
expression levels increase when HEK293 cells are exposed to MnCl2 (135). Thus, ATP13A2 40 
regulates and is controlled by the intracellular Mn
2+
-concentration providing a strong link 41 
between ATP13A2 and Mn
2+
 homeostasis. Although these observations indicate that 42 
ATP13A2 is implicated in the removal pathway for Mn
2+
, the available evidence that 43 
ATP13A2 would be a Mn
2+
 transporter remains circumstantial since no direct Mn
2+
 transport 44 
or lysosomal Mn
2+
 uptake has been demonstrated.  45 
 46 
For instance, instead of possibly transporting Mn
2+
 directly, ATP13A2 might influence other 47 
Mn
2+
 removal pathways which can depend on vesicular transport and/or other Mn
2+
 carriers. 48 
It is clear that efficient Mn
2+
 resistance in yeast depends on all steps in the secretory pathway 49 
involving proteins of vesicle-mediated transport, vacuolar organization and chromatin 50 
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remodeling (115). This suggests that Mn
2+
 removal may occur mainly via vesicular transport 1 
routes. In the brain, Mn
2+
 detoxification also depends on several members of the solute carrier 2 
(SLC) family including the proton coupled transporters SLC11A2/DMT1/NRAMP2 and 3 
SLC40A1/ferroportin, the putative Zn
2+
/Mn
2+
 transporter SLC30A10/ZnT10 and 4 
SLC39A14/ZIP14 (152, 153). These proteins are involved in Mn
2+
 transport and typically 5 
carry several metal species. SLC members are involved in the transport of several divalent 6 
metal cations, such as Zn
2+
, Mn
2+
, Fe
2+
, Ni
2+
, Cu
2+
, Co
2+
 and Cd
2+
. This is also the case for the 7 
transferrin receptor (TfR) carrying Fe
2+
 and trivalent Mn
3+
 (153) and for the Secretory 8 
Pathway Ca
2+
/Mn
2+
-transport ATPase SPCA1/PMR1 (151). The relative importance of all 9 
these Mn
2+
 transporters or removal pathways in the brain or how ATP13A2 affects these 10 
pathways remains to be determined.  11 
 12 
Several Mn
2+
 transport routes were studied in neuronal cells. Mn
2+
 is sequestered into the 13 
Golgi/secretory pathway compartments by SPCA1/PMR1, which also belongs to the P-type 14 
ATPase family (P2-type) (151). So far, the two SPCA isoforms SPCA1 (ubiquitous) and 15 
SPCA2 (secretory cells) are the only known P-type ATPases in animals that transport Mn
2+
 in 16 
intracellular stores with a high affinity. As such, SPCA1 might be implicated in the removal 17 
of toxic Mn
2+
 from neurons through the secretory pathway (151). However, SPCA expression 18 
levels decrease with Mn
2+
-exposure and SPCA activity is inhibited by high concentrations of 19 
Mn
2+
, suggesting that other Mn
2+
-removal mechanisms may prevail in neurons (154). 20 
 21 
The ubiquitous ZIP14 is present in the plasma membrane and promotes Mn
2+
 uptake in 22 
SHSY5Y neuroblastoma cells. Conversely, SLC30A10 controls Mn
2+
 secretion in SHSY5Y 23 
cells, which is thought to be a Mn
2+
 transporter (155). Mutations in SLC30A10 cause extreme 24 
neurotoxic accumulation of Mn
2+
 in liver and brain triggering dystonia and parkinsonism 25 
(155). The subcellular localization of SLC30A10 matches with different compartments, such 26 
as the Golgi system, endosomes and the plasma membrane (155). The human SLC30A10 27 
complements defective Mn
2+
 uptake in yeast cells lacking the Ca
2+
/Mn
2+
 ATPase PMR1 (156) 28 
and the endogenous SLC30A10 expression increases with Mn
2+
 exposure in HepG2 29 
hepatocellular carcinoma cells. These observations provide a strong link between SLC30A10 30 
and maintaining Mn
2+
 homeostasis. Finally, neurons also take up Fe
2+
 and trivalent Mn
3+
 via 31 
DMT1 and TfR (153).  32 
 33 
7.2.2. Is ATP13A2 a Zn
2+
 transporter? 34 
 35 
Besides Mn
2+
, Ypk9p protects yeast against other heavy metals, including Zn
2+
, Cd
2+
, Ni
2+
, 36 
and Se
2+
 (29, 114, 116). In mammalian cell systems, a link between ATP13A2 and Mn
2+
, 37 
Ca
2+
, Cd
2+
, Zn
2+
 or Ni
2+
 homeostasis has been reported. A protective effect of ATP13A2 38 
overexpression towards Ni
2+
 and Mn
2+
 in mammalian NLF cells was described (141), whereas 39 
the knockdown of ATP13A2 increases the sensitivity of SHSY5Y cells towards Zn
2+
, but 40 
strangely not Mn
2+
. This challenges the view that ATP13A2 would be a Mn
2+
 transporter. 41 
Peptide fragments of ATP13A2 bind Mn
2+
, Zn
2+
 and copper (157). ATP13A2 also regulates 42 
basal and Cd
2+
-induced intracellular Ca
2+
 levels in neurons (107).  43 
 44 
Several recent studies underscored a strong link between ATP13A2 and Zn
2+
 homeostasis 45 
(27, 116, 143). Thus, Zn
2+
 is another strong candidate ligand for ATP13A2-mediated 46 
transport. Neurons are sensitive to both Zn
2+
 deficiency and excess (158) and Zn
2+
 levels are 47 
increased in PD (159). Fibroblasts carrying homozygous or compound heterozygous 48 
ATP13A2 disease mutations and also patient-derived olfactory neurospheres (hONs), mouse 49 
primary embryonic cortical neurons and SHSY5Y cells with ATP13A2 knock down are 50 
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highly sensitive to Zn
2+
 exposure, whereas sensitivity to Mn
2+
 is less pronounced (27, 116, 1 
143). In addition, the expression of endogenous ATP13A2 in primary neurons was elevated in 2 
the presence of Zn
2+
 (27). In conditions of Zn
2+
 overload, the acidic or LC3-positive vesicles 3 
of ATP13A2
-/-
 cells accumulate less Zn
2+
 (27, 143). Conversely, via X-ray fluorescence 4 
microscopy total intracellular Zn
2+
 levels were estimated to be 60% higher in ATP13A2
-/-
 5 
hONs than in control cells (116). This would suggest that ATP13A2 contributes to Zn
2+
 efflux 6 
from the cell.  7 
 8 
Whether ATP13A2 pumps Zn
2+
 directly or rather affects other Zn
2+
 transporters or vesicular 9 
transport remains to be clarified. In the hONs, the majority of known secondary Zn
2+
 10 
transporters were upregulated in ATP13A2
-/-
 cells, pointing to a severe Zn
2+
 dyshomeostasis. 11 
These include 9 members of the SLC30 family of Zn
2+
 transporters (ZnTs) that mediate Zn
2+
 12 
efflux and 14 members of the SLC39 family of ZRT/IRT-related proteins (Zn
2+
 importing 13 
proteins, ZIP) that facilitate influx of Zn
2+
 (143). It is unclear how much of the altered 14 
expression pattern of these Zn
2+
 transporters explains the mislocalization of Zn
2+
 in ATP13A2 15 
deficient cells.  16 
 17 
Nevertheless, the result of impaired ATP13A2 activity is a rise in cytosolic Zn
2+
 18 
concentrations. Zn
2+
 dyshomeostasis has been associated with a variety of neurological 19 
disorders (158). This affects multiple cellular functions including the mitochondria (143) and 20 
lysosomes (27), making it difficult to assess the underlying mechanism of ATP13A2-21 
mediated Zn
2+
 protection. Zn
2+
 induces lysosomal dysfunction, which negatively impacts on 22 
lysosomal pH, lysosomal proteolysis and accumulation of α-synuclein (27). Loss of 23 
ATP13A2 also leads to lysosomal dysfunction, which potentiates the Zn
2+
-related effects (26, 24 
27).  25 
 26 
Zn
2+
 is not involved in redox reactions and therefore does not generate oxidative stress by 27 
itself. However, excessive mitochondrial Zn
2+
 uptake in conditions of high Zn
2+
 exposure 28 
inhibits several enzymes and complexes of the mitochondria leading to the production of 29 
ROS. This imposes oxidative stress, which can induce cell death (143). As mentioned above, 30 
the loss of ATP13A2 is associated with mitochondrial dysfunction, which is related to 31 
impaired mitochondrial clearance, presumably due to insufficient lysosomal degradation (107, 32 
142, 144). The improper cytosolic removal of Zn
2+
 in ATP13A2
-/-
 cells might further impose 33 
mitochondrial stress, triggering severe ROS production (143). Moreover, an increased 34 
accumulation of failing mitochondria in ATP13A2
-/-
 cells in conditions of Zn
2+
 exposure may 35 
contribute to the increased sensitivity of Zn
2+
. The extensive mitochondrial dysfunction and 36 
fragmentation may lead to ATP depletion and/or ROS production resulting in cellular 37 
degeneration. Importantly, treatment with an antioxidant completely abolishes Zn
2+
-induced 38 
cell death in ATP13A2
-/-
 cells, indicating that the ROS production during Zn
2+
-induced 39 
mitochondrial failure largely accounts for the toxic effects of Zn
2+
 (143).  40 
 41 
In conclusion, it appears that the Zn
2+
 phenotype of ATP13A2
-/-
 cells can largely be explained 42 
without imposing that ATP13A2 is a Zn
2+
 transporter. 43 
 44 
7.2.3. Is ATP13A2 a Mg
2+
 transporter? 45 
 46 
The ATP13A2 homologue Kil2 in Dicytostelium discoideum, a phagocytic bacterial predator, 47 
is required for Mg
2+
-dependent killing of ingested Klebsiella (160). Also the ATP13A2 48 
homologue CATP-6 in C. elegans has been implicated in Mg
2+
 uptake (132). In a purified 49 
system, the ATPase activity of the P5A ATPase Spf1p in S. cerevisiae is stimulated by Mg
2+
 50 
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ions (161). These observations might indicate that Mg
2+
 plays a role in both P5A and P5B 1 
ATPases. However, all P-type ATPases require Mg
2+
 for proper ATP coordination and 2 
phosphorylation of the conserved Asp in the P-domain (38). So for any P-type ATPase it is 3 
difficult to discriminate between transport or non-transport related effects of Mg
2+
 on the 4 
ATP-hydrolytic activity.  5 
 6 
7.2.4. Is ATP13A2 a H
+
 transporter? 7 
 8 
ATP13A2 is present in acidic compartments. Because loss of ATP13A2 leads to an elevated 9 
lysosomal pH, ATP13A2 might be involved in organellar acidification (26, 27). However, 10 
whether the lysosome would require additional H
+
 pumps is questionable, as lysosome 11 
acidification primarily depends on the activity of V-type ATPases, which are highly efficient 12 
and abundant lysosomal H
+
 pumps. V-type ATPases also work together with Cl
-
 channels for 13 
generating the steep H
+
 gradient in the lysosome (162). 14 
 15 
7.2.5. Can the ATP13A2 TM sequence support ion transport? 16 
 17 
Establishing conclusively that ATP13A2 is a cation transporter will depend on a biochemical 18 
characterization of the purified pumps reconstituted in lipid vesicles that allow for 19 
measurements of transport. So far, we can only question whether the ATP13A2 protein 20 
supports Zn
2+
, Mn
2+
, Mg
2+
 or H
+
 transport. As explained before, the M4 region in P-type 21 
ATPases is critically involved in substrate coordination and specific M4 sequence motifs 22 
correlate well with substrate specificity. We first compared the sequence of ATP13A2 with 23 
SPCA, an established P-type Mn
2+
 transport ATPase (Fig. 4). M4 of ATP13A2 (PPALP) 24 
strikingly differs from the SPCA M4 region (PEGLP). The Glu residue that coordinates Mn
2+
 25 
and serves as a gating residue is absent in ATP13A2 and is replaced by a hydrophobic residue 26 
that is difficult to reconcile with ion binding. However, ion-coordination in SPCA not only 27 
depends on M4, but also involves oxygen atoms of the peptide backbone and polar residues 28 
positioned on M5 and M6 (151). In ATP13A2, at least one conserved negatively charged 29 
residue is found in M6 and conserved polar residues are found on M4, M5 and M6, which in 30 
theory could support ion coordination (Fig. 4) (52). Notably, critically conserved Asp residues 31 
in the M6 segment of the P3 plasma membrane H
+
-ATPase (163) and the P2 Ca
2+
-ATPases 32 
(37) play a role in respectively H
+
 coordination and Ca
2+
 coordination.  33 
 34 
Coordination of Zn
2+
 typically involves His and/or Cys residues (164). Also in the P-type 35 
ATPase heavy metal transporters, conserved Cys residues are found in the M4 region (a CPC 36 
motif in the CopA copper transporter) (45). No obvious conserved His, Cys or even a Met are 37 
found in the TM region of ATP13A2, questioning whether coordination of Zn
2+
 may occur. 38 
However, a striking similarity is observed between ATP13A2 and the P1B heavy metal P-39 
type ATPases, which both have extra N-terminal helices in common (45, 52). In the CopA 40 
copper transporter, the N-terminal platform recruits metal-chaperones for copper delivery 41 
(45). Whether metal chaperones would bind ATP13A2 remains to be tested. Several putative 42 
ATP13A2 interactors were identified with a split-ubiquitin yeast two hybrid screening (145) 43 
and several genetic interactions for YPK9 were identified in yeast (115), but no obvious metal 44 
chaperones or proteins involved in metal transport were found. 45 
 46 
In conclusion, at least some residues in the M-region of ATP13A2 might support ion binding, 47 
but the overall composition significantly differs from other P-type Mn
2+
 and Zn
2+
 transporters. 48 
So until strong biochemical evidence becomes available, we may need to consider other 49 
possibilities. 50 
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 1 
7.3. Is ATP13A2 a late endosomal/lysosomal flippase? 2 
 3 
Among the P-type ATPases the 14 members of the P4 ATPases transport other ligands than 4 
inorganic cations. Members of this subfamily flip phospholipids from one membrane leaflet 5 
to the other. Because P5 ATPases phylogenetically are more related to P4 ATPases than to 6 
any other P-type ATPase subfamily (Fig. 1), it may be interesting to consider the possibility 7 
that P5 ATPases likewise might be involved in lipid or organic ion transport. The structural 8 
requirements of P4-type flippases are only just emerging and candidate residues have been 9 
identified that are important for lipid transport (165-167). An Ile residue in the conserved P4 10 
sequence motif on M4 (PISL) appears important for the binding and translocation of the 11 
phospholipid and shows functional analogy to a conserved Glu in M4 of P2-type ATPases 12 
that in these pumps serve as a gating residue (168). At this point it remains hard to say 13 
whether P5B-type ATPases fulfill the sequence requirements of a typical flippase. 14 
Remarkably, a Pro in the M4 motif of the P5 is found at the position of the conserved Glu in 15 
P2 and Ile in P4.  16 
 17 
Amongst other possible hypotheses, we should consider the possibility that ATP13A2 might 18 
be a flippase that transports a lipid or another organic molecule from one membrane leaflet to 19 
the other. Such an activity might in turn control vesicular dependent processes that regulate 20 
ion homeostasis, exosome formation, mitophagy/autophagy and α-synuclein clearance. 21 
 22 
As a putative (lipid) flippase, ATP13A2 might alter membrane curvature, alter lipid 23 
dynamics, organize lipid microdomains or expose/remove important signaling molecules at 24 
one or the other membrane leaflet (34, 87), which might for instance regulate α-synuclein 25 
membrane interactions. Moreover, ATP13A2 is implicated in mitochondrial clearance and 26 
exosome formation at the site of the late endosome, MVB and lysosome. A putative (lipid) 27 
flippase might here be strategically important as these organelles undergo continuous vesicle 28 
forming and vesicular fusion events to deliver, sort or remove cargo. This might require a 29 
tight regulation of membrane dynamics. At the end station for autophagsome delivery, 30 
ATP13A2 might control the fusion process of the autophagosomes. ATP13A2 might for 31 
instance compose a fusion-compatible lipid microdomain or expose important signaling 32 
molecules required for fusion. Alternatively, changes in the lysosomal lipid distribution may 33 
regulate autophagy pathways, which are known to be sensitive to changes in the lipid 34 
environment (169, 170). ATP13A2 might regulate micro-autophagy, a process depending on 35 
membrane invagination to take up cargo for degradation. It might also be involved in the 36 
formation of intraluminal vesicles of the MVBs which impacts on α-synuclein removal (116).  37 
 38 
8. Conclusion 39 
 40 
Although the cell biological context in which ATP13A2 is involved is gradually emerging, 41 
studying the molecular function and substrate specificity of ATP13A2 using biochemical 42 
methods and isolated systems will be required to unravel the substrate specificity and 43 
transport properties of ATP13A2. Understanding ATP13A2 at the molecular level will reveal 44 
its link to KRS, NCL, dystonia and PD. This might open new therapeutic possibilities to treat 45 
this spectrum of disorders.  46 
 47 
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 1 
11. Legends 2 
 3 
Figure 1. Phyologenetic tree of the human P-type ATPases 4 
Phylogenetic tree based on the core protein sequences of 137 animal homologues of the 36 5 
human P-type ATPase isoforms. ATP13A2 homologues were obtained from the database 6 
Homologene http://www.ncbi.nlm.nih.gov/homologene. Core protein sequences were 7 
generated according to the methodology described in (35). The 36 human P-type ATPases are 8 
indicated. Of note, only animal isoforms are depicted, so the P3A-type ATPases, which are 9 
uniquely found in fungi and plants and the small class of bacterial Mg
+
-ATPases of the P3B 10 
group and bacterial pumps belonging to P1A are not represented. The phylogenetic tree was 11 
rendered using www.phylogeny.fr (171, 172). 12 
 13 
Figure 2. General Post-Albers reaction scheme for P-type ATPases 14 
A cytosolic ligand (yellow, transported ligand 1) is transported to the extracytosolic space, 15 
whereas an extracytosolic ligand (red, counter-transported ligand 2) is imported into the 16 
cytosol. Note that the number of ligands in each direction may vary between different P-type 17 
ATPase isoforms. In short, P-type ATPases switch between two major conformations E1, 18 
with ligand binding sites facing the cytosol, and E2, with ligand binding sites facing the 19 
extracytosolic side of the membrane. The induced fit of ligand 1 binding in E1 promotes 20 
phosphorylation by Mg
+
-ATP. In this E1~P state the ligand 1 becomes occluded. The rate-21 
limiting E1~P to E2-P transition is accompanied by major conformational changes, 22 
reorienting the ligand-binding sites towards the extracytosolic space. This decreases the 23 
affinity of the binding site for ligand 1, whereas the affinity for ligand 2 is increased. As a 24 
result, ligand 1 is released into the extracytosolic space via an open exit pathway for ligand 1 25 
and the counter-transported ligand 2 can enter the binding cavity. The resulting 26 
conformational changes lead to dephosphorylation of E2P and the released inorganic 27 
phosphate is expelled. The ligand 2 becomes occluded, whereupon the pump is reset to the E1 28 
state, reducing the affinity for ligand 2. The pump can now start a new cycle.  29 
 30 
Figure 3. Topology and architecture of the catalytic subunits of P-type ATPases 31 
A. Planar topology models of the five classes of P-type ATPases (P1-P5). Nucleotide-binding 32 
domains (N, yellow), actuator domains (A, green) and phosphorylation domains (P, red) are 33 
indicated. The 6 TM helices (1-6) form the core segment of the membrane (M) domain of all 34 
P-type ATPases, which is depicted in dark blue, whereas additional N- and C-terminal helices 35 
are shown in light blue. Of note, there is one exception for the P2 ATPases, a splice variant of 36 
ATP2A2, SERCA2b, harbors an 11
th
 TM helix at the C-terminus (not shown, (47)). B. 37 
Resolved P-type ATPase crystal structures, known up until now. The Legionella pneumophila 38 
CopA copper-ATPase (PDB 3RFU), a P1B-type ATPase; the rabbit P2A-type ATPase 39 
ATP2A1 (SERCA1a, PDB 2AGV), the Squalus acanthias Na
+
/K
+
-ATPase α-subunit ATN1 40 
(PDB 3A3Y), a member of the P2C group and the Arabidopsis thaliana proton pump AHA2 41 
(PBD 3B8C) of the P3-type ATPases. N-, A-, P- and M-domains are indicated with similar 42 
colors as in the planar models. Note that the obligatory subunits of the P1A, P2C and P4 are 43 
not shown. 44 
 45 
Figure 4. Sequence comparison of the TM helices in P-type ATPases of various 46 
subfamilies 47 
The residues involved in Ca
2+
 binding in the two Ca
2+
 binding sites (site 1 and 2) in the 48 
SERCA1a Ca
2+
 pump (ATP2A1) are distributed over four TM helices: M4, 5, 6 and 8. The 49 
colored residues are part of the Ca
2+
 binding sites in ATP2A1 and numbers 1 and 2 refer to 50 
36 
 
the number of the Ca
2+
-binding site to which the residue contributes (x is contributing to both 1 
site 1 and site 2). The sequence of the M4, M5, M6 and M8 helices is compared with those of 2 
the P-type ATPases that are involved in neurological disorders. Also the yeast P5 ATPases 3 
Spf1p and Ypk9p, the Ca
2+
/Mn
2+
-ATPase SPCA as well as the proton pump AHA2 are 4 
included for comparison. M4 shows the highest degree of conservation. Highlighted in red are 5 
conserved residues as compared to the ATP2A1 Ca
2+
 binding site sequence, whereas in 6 
yellow the non-conserved residues are indicated. For each subfamily, a signature motif can be 7 
recognized in M4, which corresponds well with the substrate specificity. The PPELP and 8 
PPALP sequences of P5A- and P5B-type ATPases have little in common with other P-type 9 
ATPase signature motifs, which might indicate that the transported ligand is significantly 10 
different. 11 
 12 
Figure 5. Genetic interactions of YPK9 in S. cerevisiae grouped according to cellular 13 
localization and function 14 
Summary of the known genetic interactions of the yeast ATP13A2 orthologue YPK9. The 15 
data were collected from the yeast genome database (http://yeastgenome.org, see 16 
Supplementary Table 1) and were classified using BioGrid (http://thebiogrid.org) according to 17 
organellar distribution and function.  18 
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